Compare CSTE & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | SLGL |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 69.1M |
| IPO Year | 2012 | 2018 |
| Metric | CSTE | SLGL |
|---|---|---|
| Price | $1.50 | $41.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 471.1K | 19.1K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $400,656,000.00 | $18,970,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $0.86 | $4.02 |
| 52 Week High | $5.04 | $52.26 |
| Indicator | CSTE | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 70.95 | 66.91 |
| Support Level | $0.86 | $38.13 |
| Resistance Level | $1.05 | $37.95 |
| Average True Range (ATR) | 0.13 | 3.88 |
| MACD | 0.07 | 0.86 |
| Stochastic Oscillator | 92.44 | 85.01 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.